The present debate on chemicals with Hormonal activity, often termed 'endocrine disruptors', is highly controversial and includes challenges of the present paradigms used in toxicology and in hazard identification and risk characterization. In our opinion, chemicals with hormonal activity can be subjected to the well evaluated health risk characterization approach used for many years including adverse outcome pathways. Many of the points arguing for a specific approach for risk characterization of chemicals with hormonal activity are based on highly speculative conclusions. These conclusions are not well supported when evaluating the available information.
The potential impact of environmental chemicals on the endo crine system in humans is an area of intensive and controver sial debate. In this context, scientists from the area of endocrinology have claimed that approaches to hazard assess ment widely accepted in toxicology are 'outdated' and have questioned the procedures applied in health risk assessment by regulatory agencies worldwide (Myers et al., 2009; Vandenberg et al., 2009 Vandenberg et al., , 2010 Vandenberg et al., , 2012 . This debate has resulted in proposed reg ulations in Europe based on the 'precautionary principle' and in discussions on classification of chemicals with hormonal activ ity as 'endocrine disruptors'. As pointed out in the 2002 WHO/ IPCS report and by the Scientific Committees of the European Commission (CSTEE, SCHER) 'endocrine disruption' is not a toxi cological endpoint per se, but one of the many modes of action which may result in adverse effects. Accordingly, modes of action should not be used as a basis for classification and label ing of chemicals, and the special classification of a chemical as 'endocrine disruptor' is inconsistent with the established and proven procedures of chemical classification and labeling, and thus should be avoided.
In a recent editorial (Dietrich et al., 2013) published in several toxicology oriented journals and in an open letter (Open Letter, 2013) to the then Chief Scientific advisor of the EU commission, Prof. Anne Glover, many colleagues have already expressed their concerns regarding the proposed inappropriate regulation. The letter was signed by numerous researchers and teachers in phar macology and toxicology. Many of them also have been active in advisory groups charged with risk assessment and/or partici pated in expert teams for the topic of 'endocrine disruption' at the level of the European Union or the OECD. In response to this editorial and the open letter (Dietrich et al., 2013; Open Letter, 2013) , several articles and press releases were published in favor of hazard based regulation and classification of 'endocrine dis ruptors' (Garwood, 2014; Gore, 2013; Grandjean and Ozonoff, 2013; Horel and Bienkowski, 2013) . Many of these articles contained foremost irrelevant ad personam attacks and included only a lim ited scientific discussion of the issues that were raised.
Aspects of approaches to health risk assessment for 'endo crine disruptors' (Borgert et al., 2013; Dekant and Colnot, 2013; Dietrich, 2010; EU SCCS, 2014; Greim, 2005; Hengstler, 2014; Open Letter, 2013; Testai et al., 2013) have been published. Since the de bate remains controversial and apparently in deadlock, we wish to expand the discussion of the approaches to health risk assess ment for 'endocrine disruptors' into the toxicology community. A new article titled 'A path forward in the debate over health im pacts of endocrine disrupting chemicals' (Zoeller et al., 2014) pro poses a 'way forward' in the discussion regarding potential health impacts of 'endocrine disruptors'. The proposal by Zoeller et al. (2014) to engage in a rational debate based on principles of science is highly appreciated since a pathway forward is needed.
However, the Zoeller et al.'s proposal to delineate a scientifi cally sound way forward is again unnecessarily flawed by an imbalanced presentation of available information and some misinterpretation of statements. For example, while Zoeller et al. (2014) mention that the report published by WHO/UNEP (WHO/UNEP, 2012) was criticized, they neither mention who criticized this report nor the reasons for the critique. The critique (Lamb et al., 2014) was developed by a group of experts including some of the main authors of the first WHO/UNEP (WHO/UNEP, 2002) report. Their main concerns regarding the WHO/UNEP (2012) report were:
• The 2012 WHO/UNEP report does not follow the weight of evi dence approach recommended by the 2002 WHO/UNEP report and presents data and controversial topics (i.e. low dose effects, nonmonotonic dose response) in an unbalanced way.
• In the 2012 report, 'endocrine disruption' is often postulated to occur based on an exposure assessment or a potential mecha nism for 'suspect' chemicals despite a lack of support for a causal relationship as requested by the definition of 'endocrine disruption'.
• In the 2012 report, a causative role of 'endocrine disruption' is of ten inferred by combinations of a series of unrelated facts, which collectively do not demonstrate causation.
• In the 2012 report, 'endocrine disruption' is implicated as the ba sis for trends in disease incidence or prevalence without ade quately considering other potential risk factors.
• Basic principles of dose and potency are often ignored.
Unfortunately, Zoeller et al. (2014) again do not provide a bal anced approach of available data in their proposal. Scientists in the field of toxicology, pharmacology, and risk assessment are striving to provide for a weighing of appropriate evidence to allow a realistic evaluation of health risks for humans (EFSA, 2013; EU SCCS, 2014) . As emphasized earlier (Dietrich et al., 2013) and corroborated later (Lehman McKeeman and Kaminski, 2013) , scientists owe it to their scientific integrity to provide the best evaluation of data possible. Therefore, the 2002 WHO/UNEP report demanded that a review of all data on endo crine disruption is to be appropriately performed according to the well established principles of data evaluation. This was not adequately performed in the WHO/UNEP report of 2012 and is also missing in the Zoeller et al.'s (2014) article.
Regarding the views expressed by Zoeller et al., we would like to comment on aspects that remain controversial:
• As in previous papers, Zoeller et al. present the endocrine system as a unique biological system, which should require special con siderations in hazard identification and risk characterization that are not relevant when assessing other somatic targets for toxicity. However, basic research in pharmacology and toxicol ogy on endocrine active compounds as well as decades of clinical experience e.g. the use of contraceptives and hormones in the treatment in osteoporosis show that this is not the case. The extensive database on the outcome of prenatal diethylstilbestrol (DES) exposure (reviewed by Golden et al., 1998; Hoover et al., 2011) show a high degree of concordance between effects ob served in humans and in rodent models. Moreover, animal stud ies with perinatal exposure to DES are consistent with dose related effects for adverse outcomes (Dietrich, 2010) . This is also documented for other potent drugs, such as tamoxifen and antiandrogens (Iguchi et al., 1986; Imperato McGinley et al., 1992; Newbold et al., 1997) .
• Interference of a chemical with hormone mediated pathways is one of many possible modes of action resulting in adverse (or therapeutic) effects after chemical exposures. The many other modes of action elucidated by mechanistic toxicology also include potential windows of susceptibility, potentially sensitive subgroups, complex mechanisms, and often many mechanistic steps with limited understanding (Klaassen, 2013) . Therefore, well planned and conducted research toward a better under standing of all modes of actions responsible for toxicities of chemicals is needed. Only on such a basis, can we integrate the presently available modes of action into reasonable risk assess ment approaches to support causality (Carmichael et al., 2011; Dekant and Colnot, 2013; Testai et al., 2013) .
• Many of the known modes of action in toxicology include receptor mediated mechanisms, e.g. chlorinated dioxins, many chemicals acting as enzyme inducers, and many chemicals in terfering with neurotransmission. In addition, modern toxicol ogy has developed largely from studies of drug safety and safety assessment of medicines remains one of the major fields of toxi cology. Numerous drugs act through cellular receptors. Thus, there is abundant information on the principles of receptor inter actions, which is often ignored in the dispute on 'endocrine dis ruptors'. Indeed, relevant and longstanding state of the art experience is available in receptor mediated effects in toxicology and pharmacology.
• The limitations of epidemiological data in health risk characteri zation regarding environmental exposures are the low sensitiv ity of epidemiology, issues with study design, exposure assessment, multiple endpoints of potential relevance, and the presence of confounders (Mirmira and Evans Molina, 2014 ).
Yet, careful follow up of the DES exposed cohorts was able to provide cumulative risk estimates for several adverse outcomes which had been documented in females and males (Hoover et al., 2011; Palmer et al., 2009) . However, DES is a highly potent estro gen and was applied in high doses during pregnancy (Dietrich, 2010) . In contrast, doses of chemicals with potential hormonal activity received from the environment are very low and most of these compounds have a very low potency (EFSA, 2015; Safe, 1995 Safe, ,2000 .
• We agree with the conclusion regarding the WHO/IPCS definition for adversity as useful basis for further discussions, but also sup port the WHO/IPCS definition for an 'endocrine disruptor' as does EFSA and SCCS (EFSA, 2013; EU SCCS, 2014) . A logical conse quence of using these definitions is that potency is expressed by a benchmark dose (or NOAEL) and is derived from the dose incidence curve for adverse effects in intact animals from appro priate toxicity studies. This has been integrated in potency assessments for both synthetic and natural chemicals for de cades. Apparently, there is agreement on the use of NOAELs or benchmark doses as indicators of potency in risk assessment, and, in fact, one of the authors of the Zoeller's article (2014) has used NOAELs and benchmark doses to assess relative potency in cumulative risk assessments (Kortenkamp and Faust, 2010) .
• Using adverse effects in intact animals for hazard assessment will also permit to identify chemicals with hormonal activity where the parental compound does not show interactions with hormone receptors, but where metabolites, often formed by complex pathways, are hormonally active and may cause ad verse effects (Reinen and Vermeulen, 2015; Reinen et al., 2011; van Liempd et al., 2006) .
• Theoretical considerations and decades of experience with nu merous chemicals from many structural classes with many dif ferent modes of action provide strong evidence of thresholds (Borgert et al., 2013) . The existence of thresholds is plausible since endogenous hormones are active in the presence of a 10 5 to 10 9 M excess of other endogenous chemical constituents.
Many of these other endogenous chemicals have low affinities to hormone receptors or even have some marginal intrinsic activ ity. When the affinity of an endocrine active chemical toward a specific receptor and its internal concentration are orders of magnitude lower compared with physiological concentrations of respective hormones, they are very unlikely to cause adverse effects via this specific receptor.
• Regarding the mechanistic interpretation of Zoeller et al. (2014) for 'endocrine disruption', the authors focused on the potential influence of an 'endocrine disruptor' on hormone 'action' which they equate to 'hormone receptor activation'. This approach is inconsistent with the way toxicology and generally accepted risk characterization procedures describe toxicologically relevant processes in terms of an adverse outcome pathway (OECD, 2013). Zoeller et al. seem to imply that any direct or indirect interaction with hormone action should be considered as adverse. In reality, by applying an adverse outcome pathway approach, such inter actions can only be regarded as possible molecular initiating events. Zoeller et al. disregard the further description of events leading or not leading to a possible adversity toward the func tionality of the integrated systems.
• Guideline studies following OECD, US EPA, and European regula tions, or performed following guidance by the International Committee on Harmonization for pharmaceuticals, are estab lished tools for hazard identification. Studies following such guidelines determine a variety of endpoints related to adversity.
A wealth of experience exists regarding the interpretation of results from such studies and their integration into risk charac terization. In addition, detailed reporting of raw data from such studies is available and well evaluated and validated methods are used for all determinations. We are aware that the guideline studies have limitations and represent compromises. We agree that, from a scientific view, it may be desirable to expand such studies and additionally include a variety of molecular end points, which is already performed in some studies, such as the 'BPA Clarity' project (Birnbaum et al., 2012) . However, it remains to be demonstrated whether these additional molecular end points are more sensitive than the adverse effects determined in guideline studies and more importantly, whether they can be ex trapolated to humans.
• The point made by Zoeller et al. that nonguideline studies are not considered in risk assessments is not valid. The US EPAs IRIS as sessments, REACH dossiers, EFSA evaluations, and most others risk assessments strive to use all available data including mech anistically oriented nonguideline studies. An assessment of reli ability of studies, consistency of the database, and a weight of evidence approach in the evaluation of inconsistent databases (EFSA, 2015) is established in hazard and risk assessment world wide and was specifically embraced by the WHO/UNEP report on 'endocrine disruption' in 2002.
• The comments about differences between adverse effects be tween synthetic and natural chemicals have no scientific basis. Toxicity is governed by chemical structure and the possibility of a chemical to interact with biological systems, but not its origin. When appropriately tested, toxicity profiles of hormonally active natural compounds are very similar to those of industrial chemi cals with some hormonal activity (Belli et al., 2010; Delclos et al., 2009; Latendresse et al., 2009; Tyl et al., 2008a, b; Zhao et al., 2013) . Interestingly, many natural chemicals (e.g. isoflavones, steroids, zearalenones) are more potent than the typical industrial chemi cal with consumer exposures. Thus, just like for industrial chem icals, these compounds produced by nature also need to be subjected to the process of a scientifically based risk assessment.
In conclusion, appropriately designed and conducted toxic ity studies must include determination of the potency by which a chemical induces adverse effects. This inherently includes po tential adverse effects on the endocrine system, which could manifest as reproductive and developmental toxicities. Whenever such toxicities are identified based on well developed and robust endpoints, this will result in the classification of the respective chemical as a 'Reproductive/Developmental Toxicant'.
We strongly support a rational debate based on factual data and established principles of science and specifically of phar macology and toxicology. Such principles remain relevant to as sess potential health impacts of chemical exposures, and only the application of such principles will permit a path forward in discussing the potential health impacts of 'endocrine disruptors'.
